Since 1976, Genentech has been a leader in the field of biotechnology. We discover, develop, manufacture, and commercialize medicines to treat patients with serious and life-threatening medical conditions.
With our reinvestments in revenue, we have helped to maintain our innovations and are dedicated to creating more breakthroughs in ophthalmology.
CHf=confoederatio helvetica franc.
Genentech is dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer, the first medicine for primary progressive multiple sclerosis, and the first FDA-approved antibody therapy for various retinal diseases.
Since 1985, Genentech has donated more than $3.5 billion in free medicine.
At Genentech, we are committed to innovating beyond the current standards of care to transform how patients experience ophthalmic care.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.